References
- Chang RJ, Heindel JJ, Dunaif A, eds. Polycystic ovarian syndrome. New York: Marcel Dekker, Inc; 2002:361–5
- Dahlgren E, Friberg LG, Johansson S. Endometrial carcinoma; ovarian dysfunction – a risk factor in young women. Ere J Obstet Gynecol Reprod Biol 1991;41:143–50
- The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 concensus on diagnostic criteria and long-term health risks related to PCOS. Hum Reprod 2004;19:41–7
- Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012;27:1327–31
- Shafiee MN, Chapman C, Barrett D, et al. Reviewing the molecular mechanisms which increase endometrial cancer (EC) risk in women with polycystic ovarian syndrome (PCOS): time for paradigm shift? Gynecol Oncol 2013;131:489–92
- Shafiee MN, Khan G, Ariffin R, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? Gynecol Oncol 2014;132:248–53
- Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation – implications for a novel treatment strategy. Gynecol Oncol 2010;116:92–8
- Tan BK, Adya R, Chen J, et al. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab 2011;96:808–16
- Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112:465–7
- Dumont P, Leu JI, Della Pietra AC, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357–65
- Klug SJ, Ressing M, Koening J, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 2009;10:772–84
- Zhang Z, Wang M, Wu D, et al. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 2009;120:509–17
- Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299–303
- Soslow RA, Shen PU, Chung MH, Isacson C. Distinctive p53 and MDM2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998;17:129–34
- Chon HS, Marchion DC, Xiong Y, et al. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol 2012;124:119–24
- Zhang R, He Y, Zhang X, et al. Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions. Cancer Lett 2012;314:155–65
- Takai N, Desmond JC, Kumagai T, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004;10:1141–9
- Konishi I, Koshiyama M, Mandai M, et al. Increased expression of LH/hCG receptors in endometrial hyperplasia carcinoma in anovulatory women. Gynecol Oncol 1997;65:273–80
- Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod BioMed Online 2009;19:398–405
- Haas DA, Carr BR, Attia GR. Effect of Metformin on BMI, menstrual cyclicity and ovulation induction in women with polycystic ovary syndrome. Fertil Steril 2003;79:469–81
- Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol 2003;101:785–93
- Tas M, Kutuk MS, Serin IS, et al. Comparison of antiproliferative effects of metformin and progesterone on estrogen-induced endometrial hyperplasia in rats. Gynecol Endocrinol 2013;29:311–14
- Gunter MJ, Hoover DR, Yu H, et al. Prospective evaluation of insulin and insulin like growth factor-I as risk factors of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008;17:921–9
- Levav-Cohen Y, Haupt S, Haupt Y. MDM2 in growth signaling and cancer. Growth Factors 2005;23:183–92